Lead Sponsor

University of Michigan

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult outpatients (18 years and older) that carry a diagnosis of IBD and confirmed in the electronic health record (EHR) as receiving IBD-targeted treatment
•IBD-targeted treatment include 5-aminosalicylates, thiopurines, biologics, or small molecules such as Janus kinase inhibitor (JAK) inhibitors or sphingosine-1-receptor modulators.
•Self-report abdominal pain with an average severity ≥ 2 on a 0-10 pain scale over the last 24 hours,
•Participants are willing and able to pick-up and drop-off VR equipment at University of Michigan (UM)

•Patients that do not report pain (i.e., score\<2) as they are less likely to benefit from VR-directed BGBT
•Patients with a history of conditions that could potentially be harmed by VR including seizures/epilepsy, loss of awareness, binocular vision loss, current pregnancy, or uncontrolled cardiac (e.g., arrhythmia, coronary artery disease) or neurological/cerebrovascular disease.

Related studies

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

NCT06553053 · Crohn's Disease Relapse, Inflammatory Bowel Diseases

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

NCT05986136 · Inflammatory Bowel Diseases

NCT06266663 · Inflammatory Bowel Diseases

Outpatient VR (Virtual Reality)-Brain-gut Behavioral Therapies (BGBT) in Inflammatory Bowel Disease (IBD)